Perrigo (PRGO) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Perrigo (NYSE: PRGO) in the last few weeks:

  • 3/12/2018 – Perrigo was given a new $105.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 3/5/2018 – Perrigo had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $83.00 price target on the stock, up previously from $82.00.
  • 3/5/2018 – Perrigo was given a new $98.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 3/5/2018 – Perrigo was given a new $105.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 3/1/2018 – Perrigo was given a new $107.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/27/2018 – Perrigo was given a new $105.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 2/27/2018 – Perrigo had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $98.00 price target on the stock.
  • 2/23/2018 – Perrigo was given a new $107.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/16/2018 – Perrigo was given a new $107.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/9/2018 – Perrigo was given a new $107.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/1/2018 – Perrigo is now covered by analysts at Berenberg Bank. They set a “buy” rating and a $117.00 price target on the stock.
  • 1/19/2018 – Perrigo was given a new $107.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “The CDC today released updated data on the 2017-2018 Influenza Season for Week 2, ending 01/13/18 (https://www.cdc.gov/flu/weekly/).””

Shares of Perrigo stock traded down $2.01 during trading on Monday, hitting $82.22. The company had a trading volume of 864,764 shares, compared to its average volume of 1,052,453. The company has a current ratio of 1.96, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Perrigo Company plc has a 1 year low of $63.68 and a 1 year high of $95.93. The stock has a market cap of $11,862.42, a price-to-earnings ratio of 97.88, a PEG ratio of 1.95 and a beta of 0.82.

How to Become a New Pot Stock Millionaire

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Thursday, March 1st. The company reported $1.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.03. Perrigo had a return on equity of 11.54% and a net margin of 2.42%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same quarter in the previous year, the business earned $1.24 EPS. Perrigo’s revenue for the quarter was down 3.6% compared to the same quarter last year. sell-side analysts anticipate that Perrigo Company plc will post 5.24 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 20th. Investors of record on Friday, March 2nd will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Thursday, March 1st. This is a positive change from Perrigo’s previous quarterly dividend of $0.16. Perrigo’s payout ratio is currently 90.48%.

In other Perrigo news, VP Todd W. Kingma sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the sale, the vice president now directly owns 19,565 shares in the company, valued at approximately $1,731,893.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Uwe Roehrhoff acquired 7,500 shares of the business’s stock in a transaction on Monday, March 5th. The shares were purchased at an average price of $81.85 per share, with a total value of $613,875.00. Following the completion of the purchase, the chief executive officer now owns 4,900 shares in the company, valued at approximately $401,065. The disclosure for this purchase can be found here. 6.90% of the stock is owned by insiders.

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Receive News & Ratings for Perrigo Company plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply